Exit Notice

You are about to leave ClinicalTrials.gov and go to: Imugene (ASX: IMU) is a publicly-listed, clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. URL: https://www.imugene.com/

Click on the link to continue or return to ClinicalTrials.gov Home